Key result
Weekly paclitaxel monotherapy achieves ~30% tumor reduction in a primary pulmonary epithelioid angiosarcoma case.
Why the study?
Pulmonary epithelioid angiosarcoma is a rare, highly aggressive malignancy lacking established treatment protocols, and the use of paclitaxel for this condition had not been previously reported.
Case Report (n=1)
No
Weekly paclitaxel monotherapy achieved a clinically meaningful partial response in a frail patient with primary pulmonary epithelioid angiosarcoma, suggesting it as a viable palliative option.
Paclitaxel use in unresectable pulmonary epithelioid angiosarcoma adds one case; leaves open any efficacy signal for controlled trials.
Pulmonary epithelioid angiosarcoma is a rare, highly aggressive malignancy for which established treatment protocols are lacking. Here, we report the case of a 73-year-old male diagnosed with primary pulmonary epithelioid angiosarcoma with multiple metastases. While paclitaxel is effective for angiosarcoma, its use in pulmonary epithelioid angiosarcoma, to our knowledge, has not been previously reported. Surgery and radiotherapy were not feasible in this patient due to the advanced disease stage. Although disease progression ultimately occurred, weekly paclitaxel monotherapy achieved a clinically meaningful partial response. This case highlights that paclitaxel monotherapy selected based on the patient's overall condition can be a rational therapeutic choice to achieve objective tumor control in frail patients, serving as a valuable benchmark for individualized treatment selection in the absence of a standard treatment.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2025) conducted a case report in Primary pulmonary epithelioid angiosarcoma (n=1). Paclitaxel was evaluated on Tumor response. Weekly paclitaxel monotherapy achieved a 30% reduction in the major axis of the primary tumor, representing a partial response in a patient with primary pulmonary epithelioid angiosarcoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: